Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways

David W. Greening; Sze Ting Lee; Hong Ji; Richard J. Simpson; Angela Rigopoulos; Carmel Murone; Catherine Fang; Sylvia Gong; Graeme O’Keefe; Andrew M. Scott

doi:10.18632/oncotarget.9855

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways

David W. Greening _, Sze Ting Lee, Hong Ji, Richard J. Simpson, Angela Rigopoulos, Carmel Murone, Catherine Fang, Sylvia Gong, Graeme O’Keefe and Andrew M. Scott

PDF | How to cite

Oncotarget. 2016; 7:35497. https://doi.org/10.18632/oncotarget.9855

Metrics: PDF 2539 views | ?

Present: Due to an error during manuscript preparation, loading control (GAPDH) was omitted from Figure 5.

Corrected: Correct Figure 5 is provided below. Authors sincerely apologize for this oversight.

Original article: Oncotarget. 2015; 6(35): 38166-80. DOI: 10.18632/oncotarget.6241

Figure 5: Validation of anti-tumour effects of cetuximab and bevacizumab mediated through altered cellular metabolism. Proteins were extracted from tumour xenografts for each treatment cohort (independent from the tumour xenograft lysates performed for proteomic pro ling), obtained from pooled tumour xenograft samples from the validation experimental group (n=3). Immunoblotting analysis of the expression of ATP5B, SDC2, GPD2, ARF4 in both LIM1215 and HT-29 tumour xenograft lysates was performed (n=3; pooled for each treatment cohort, independent biological replicates performed for each antibody). Loading control (GAPDH; rabbit anti-GAPDH (Cell Signaling Technology; 1:1000)).

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 9855

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways